Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bioasis Technologies Inc. V.BTI

Alternate Symbol(s):  BIOAF

Bioasis Technologies Inc. is a multi-asset rare and orphan disease biopharmaceutical company developing clinical stage programs based on epidermal growth factors and the xB3™ platform, a proprietary technology for the delivery of therapeutics across the blood brain barrier and the treatment of CNS disorders in areas of high unmet medical need. The in-house development programs are designed to develop symptomatic and disease-modifying treatments for brain-related diseases and disorders.


TSXV:BTI - Post by User

Bullboard Posts
Comment by Sniper007on Feb 13, 2020 7:47pm
117 Views
Post# 30688656

RE:RE:RE:RE:PROMOTING THE BLUE SKY POTENTIAL OF BIOASIS? NOPE.

RE:RE:RE:RE:PROMOTING THE BLUE SKY POTENTIAL OF BIOASIS? NOPE.Rustycat, we may be considered "pre-clinical biotech" but we're not in the same boat. We HAVE gotten drugs across the BBB, just not in humans. Also, we're in the drug transportation business, not the drug development business, where most failures occur. You're suggesting the "chances are slim to get approval" but the FDA has already told Bioasis that they would look upon them favorably if the results from Bioasis’ studies meet the FDA's criteria for approval of clinical trials.

Bullboard Posts